NCT01606579View on ClinicalTrials.gov

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 30, 2016

Study Completion Date

December 30, 2016

Conditions
Acute Myeloid LeukemiaChronic Myeloid Leukemia
Interventions
DRUG

PRI-724

PRI-724

DRUG

PRI-724

PRI-724 in combination with dasatinib

DRUG

PRI-724

PRI-724 in combination with low dose ara-C therapy

Trial Locations (6)

27710

Duke University Medical Center, Durham

30322

Emory University / Winship Cancer Institute, Atlanta

77030

University of Texas M.D. Anderson Cancer Center, Houston

87106

New Mexico Cancer Care Alliance, Albuquerque

01655

University of Massachusetts Medical Center, Worcester

43210-1267

Ohio State University, Columbus

Sponsors

Collaborators (1)

inVentiv Health Clinical
All Listed Sponsors
collaborator

inVentiv Health Clinical

OTHER

lead

Prism Pharma Co., Ltd.

INDUSTRY